Recurrent seizure at 36 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 48 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 60 months or greater · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 6 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of admission during ED stay · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) probably leads to lower rate of admission during ED stay compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
1 finding from 1 review
Rate of admission 72 hrs · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) showed no clear difference in rate of admission 72 hrs compared with placebo (low certainty).
2 findings from 1 review
Time to cessation of vomiting · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
1 finding from 1 review
Rate of intravenous rehydration during ED stay · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) probably leads to lower rate of intravenous rehydration during ED stay compared with placebo (moderate certainty).
1 finding from 1 review
Rate of intravenous rehydration up to 72 hrs following discharge from ED (best ‐ worst scenario) · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) may leads to lower rate of intravenous rehydration up to 72 hrs following discharge… compared with placebo (low certainty).
1 finding from 1 review
Rate of intravenous rehydration up to 72 hrs following discharge from ED (worst ‐ best scenario) · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) may leads to lower rate of intravenous rehydration up to 72 hrs following discharge… compared with placebo (low certainty).
1 finding from 1 review
Proportion of patients with cessation of vomiting · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) probably leads to higher proportion of patients with cessation of vomiting compared with placebo (moderate certainty).
1 finding from 1 review
Revisit rate · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) showed no clear difference in revisit rate compared with placebo (low certainty).
1 finding from 1 review
Change in pain index · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral propranolol (beta-blocker) showed no clear difference in change in pain index compared with placebo; GRADE not reported.
1 finding from 1 review
Reduction in pain intensity · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral propranolol (beta-blocker) led to lower reduction in pain intensity (percentage of patients responding) compared with placebo; GRADE not reported.
2 findings from 1 review
Tchivileva et al 2010: a significantly greater percentage of patients (67.5% versus 32.5%) experienced reduction in pain intensity rating during the propranolol treatment period than the placebo treatment period (P =…
1 study · 40 participants
GRADE not reported
Tchivileva et al 2010: Reduction in pain intensity rating (primary outcome) comparing propranolol treatment to placebo treatment did not reach statistical significance (P = 0.104); pairwise differences between…
1 study · 40 participants
GRADE not reported
Reduction in pain duration (percentage of day) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral propranolol (beta-blocker) showed no clear difference in reduction in pain duration (percentage of day) compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse events ‐ treatment emergent · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Tchivileva et al 2010: at least one treatment-emergent adverse event was reported by five participants (12.5%) during the propranolol period (nausea, diarrhoea, insomnia, dizziness, fatigue) and four participants (10%)…
1 study · 40 participants
GRADE not reported
Ulcer healing · patients with Buerger's disease
(Oral or intravenous) prostanoid probably leads to higher ulcer healing compared with aspirin treatment (moderate certainty).
1 finding from 1 review
Complete relief of rest pain · patients with Buerger's disease
(Oral or intravenous) prostanoid probably leads to higher complete relief of rest pain compared with aspirin treatment (moderate certainty).
1 finding from 1 review
Rate of amputation · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in rate of amputation compared with aspirin treatment (moderate certainty).
1 finding from 1 review